The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
Obesity, Nausea and Vomiting, Postoperative
About this trial
This is an interventional prevention trial for Obesity focused on measuring Laparoscopic Gastric Sleeve, Bariatric Surgery, Nausea and Vomiting, Postoperative, Aprepitant
Eligibility Criteria
Inclusion Criteria: 18 to 65 years old. Non-smokers. Obesity with BMI > 30 kg/m2. Undergoing laparoscopic gastric sleeve. Exclusion Criteria: Documented hypersensitivity to any component of the study regimen. Current treatment with: Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole) or Propulsid (cisapride). Allergy to opioid drugs used in the anesthetic protocol. Drug or alcohol abuse. Chronic nausea and vomiting. Previous bariatric procedures.
Sites / Locations
- Hospital General Tlahuac
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Aprepitant
Placebo
Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg